切除肺腺癌的基因突变,临床特征和病理学
Ji'an Zou1,2, Wei Han1,2, Yan Hu1,2
1Department of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
World journal of surgical oncology
|January 23, 2025
概括
肺腺癌的特殊病理成分和基因突变会影响瘤的行为和患者的预后. 特别是KRAS突变与可切除肺癌患者的整体存活率显著降低有关.
科学领域:
- 在瘤学瘤学.
- 病理学 病理学 病理学
- 遗传学 是一个遗传学.
背景情况:
- 由于CT扫描的进步,肺腺癌的诊断在可切除的阶段正在增加.
- 病理检查和遗传检测是切除肺腺癌手术后的标准.
研究的目的:
- 研究特殊的病理成分,基因突变,临床特征和肺腺癌的整体存活率之间的关系.
- 分析特定瘤特征和遗传变化的预后影响.
主要方法:
- 从1118名肺腺癌患者的临床,病理和基因突变数据的回顾性分析.
- 根据病理成分和基因突变对患者进行了分类.
- 临床特征和整体生存差异的统计分析.
主要成果:
- 粘菌性,神经内分泌和差异化成分与不良预后因素 (例如,膜入侵,STAS,晚期) 和降低生存率相关.
- ALK和KRAS突变与固体结节,膜入侵,STAS和高级阶段等风险因素有关.
- KRAS突变与总生存率的下降有显著的关联,而ALK突变对这一队列的生存率没有显著影响.
结论:
- 特定的病理成分和基因突变会影响肺腺癌的生物行为.
- 这些因素导致了不同的临床特征和预后.
- 需要进一步的研究来阐明基因突变和病理组件之间的相互作用.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.0K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
相关概念视频
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Cancers Originate from Somatic Mutations in a Single Cell
11.5K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.5K
Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K
Loss of Tumor Suppressor Gene Functions
4.7K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.7K
